GSK’s partner Hansoh Pharma succeeds in Chinese Phase III SCLC ADC trial

Phase 3positivePositive

AI Analysis

Summary

Hansoh Pharma, under a GSK licensing agreement worth up to $1.71bn, has succeeded in a Phase III trial of an antibody-drug conjugate (ADC) for small cell lung cancer. The positive trial outcome de-risks the partnership and validates the therapeutic approach in the Chinese market.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Phase III trial in small cell lung cancer ADC succeeded

Importance:7/10

Sentiment:

0.75

ADConcologyChinaSCLCpartnershipPhase 3 success

Related Companies

$GSK $HNPHY

Read the original article

Published by Clinical Trials Arena on July 13, 2026 9:39 AM

Read Original